- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01785849
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
August 9, 2019 updated by: Amgen
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
508
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Research Site
-
St Leonards, New South Wales, Australia, 2065
- Research Site
-
-
Victoria
-
Parkville, Victoria, Australia, 3050
- Research Site
-
Prahan, Victoria, Australia, 3004
- Research Site
-
-
-
-
-
Graz, Austria, 8036
- Research Site
-
Linz, Austria, 4010
- Research Site
-
Wien, Austria, 1090
- Research Site
-
-
-
-
-
Aalst, Belgium, 9300
- Research Site
-
Baudour, Belgium, 7331
- Research Site
-
Bruxelles, Belgium, 1020
- Research Site
-
Leuven, Belgium, 3000
- Research Site
-
Liège, Belgium, 4000
- Research Site
-
-
-
-
-
Quebec, Canada, G1R 2J6
- Research Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6R 3J7
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Research Site
-
Montreal, Quebec, Canada, H1T 2M4
- Research Site
-
-
-
-
-
Hradec Kralove, Czechia, 500 05
- Research Site
-
Praha 4 - Nusle, Czechia, 140 00
- Research Site
-
Praha 6, Czechia, 169 00
- Research Site
-
Slavkov u Brna, Czechia, 684 01
- Research Site
-
Trinec, Czechia, 739 61
- Research Site
-
-
-
-
-
Nantes Cedex 01, France, 44200
- Research Site
-
Poitiers, France, 86021
- Research Site
-
Reims Cedex, France, 51092
- Research Site
-
Saint-Ouen, France, 93400
- Research Site
-
Salouel Cedex 1, France, 80054
- Research Site
-
-
-
-
-
Berlin, Germany, 12053
- Research Site
-
Dresden, Germany, 01307
- Research Site
-
Kiel, Germany, 24105
- Research Site
-
Villingen-Schwenningen, Germany, 78052
- Research Site
-
-
-
-
-
Baja, Hungary, 6500
- Research Site
-
Budapest, Hungary, 1115
- Research Site
-
Budapest, Hungary, 1037
- Research Site
-
Gyor, Hungary, 9023
- Research Site
-
Kaposvar, Hungary, 7400
- Research Site
-
Pecs, Hungary, 7624
- Research Site
-
-
-
-
-
Ashkelon, Israel, 78278
- Research Site
-
Nahariya, Israel, 22100
- Research Site
-
Tel Aviv, Israel, 64239
- Research Site
-
-
-
-
-
Milano, Italy, 20122
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
Pavia, Italy, 27100
- Research Site
-
San Fermo Della Battaglia (CO), Italy, 22020
- Research Site
-
Verona, Italy, 37126
- Research Site
-
-
-
-
-
Bialystok, Poland, 15-540
- Research Site
-
Warszawa, Poland, 04-141
- Research Site
-
Warszawa, Poland, 02-097
- Research Site
-
Warszawa, Poland, 02-006
- Research Site
-
Wroclaw, Poland, 51-124
- Research Site
-
Zamosc, Poland, 87-100
- Research Site
-
-
-
-
-
Saint Petersburg, Russian Federation, 191104
- Research Site
-
Saint Petersburg, Russian Federation, 196247
- Research Site
-
Saint Petersburg, Russian Federation, 198510
- Research Site
-
Saint-Petersburg, Russian Federation, 195067
- Research Site
-
Saint-Petersburg, Russian Federation, 195257
- Research Site
-
-
-
-
-
Madrid, Spain, 28046
- Research Site
-
Madrid, Spain, 28041
- Research Site
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Research Site
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08025
- Research Site
-
Barcelona, Cataluña, Spain, 08003
- Research Site
-
-
-
-
-
Cambridge, United Kingdom, CB2 2QQ
- Research Site
-
Coventry, United Kingdom, CV2 2DX
- Research Site
-
Glasgow, United Kingdom, G11 6NT
- Research Site
-
London, United Kingdom, NW3 2QG
- Research Site
-
Nottingham, United Kingdom, NG5 1PB
- Research Site
-
Salford, United Kingdom, M6 8HD
- Research Site
-
Sheffield, United Kingdom, S5 7AU
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Research Site
-
-
Arkansas
-
Pine Bluff, Arkansas, United States, 71603
- Research Site
-
-
California
-
Azusa, California, United States, 91702
- Research Site
-
Covina, California, United States, 91723
- Research Site
-
Lakewood, California, United States, 90712
- Research Site
-
Los Angeles, California, United States, 90025
- Research Site
-
Lynwood, California, United States, 90262
- Research Site
-
Northridge, California, United States, 91324
- Research Site
-
Ontario, California, United States, 91762
- Research Site
-
Panorama City, California, United States, 91402
- Research Site
-
Sacramento, California, United States, 95825
- Research Site
-
Whittier, California, United States, 90603
- Research Site
-
-
Florida
-
Pembroke Pines, Florida, United States, 33028
- Research Site
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Research Site
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- Research Site
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01107
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48236
- Research Site
-
Kalamazoo, Michigan, United States, 49007
- Research Site
-
Pontiac, Michigan, United States, 48341
- Research Site
-
Southgate, Michigan, United States, 48195
- Research Site
-
-
Mississippi
-
Tupelo, Mississippi, United States, 38801
- Research Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Research Site
-
-
Nevada
-
Reno, Nevada, United States, 89511
- Research Site
-
-
New York
-
Amherst, New York, United States, 14226
- Research Site
-
Bronx, New York, United States, 10461
- Research Site
-
Brooklyn, New York, United States, 11235
- Research Site
-
Rosedale, New York, United States, 11422
- Research Site
-
Yonkers, New York, United States, 10704
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Research Site
-
Durham, North Carolina, United States, 27704
- Research Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Research Site
-
Philadelphia, Pennsylvania, United States, 19106
- Research Site
-
Philadelphia, Pennsylvania, United States, 19118
- Research Site
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Research Site
-
Sumter, South Carolina, United States, 29150
- Research Site
-
-
Tennessee
-
Columbia, Tennessee, United States, 38401
- Research Site
-
Nashville, Tennessee, United States, 37205
- Research Site
-
-
Texas
-
Austin, Texas, United States, 78758
- Research Site
-
Fort Worth, Texas, United States, 76105
- Research Site
-
Fort Worth, Texas, United States, 76164
- Research Site
-
Grand Prairie, Texas, United States, 75050
- Research Site
-
Houston, Texas, United States, 77030
- Research Site
-
Mansfield, Texas, United States, 76063
- Research Site
-
San Antonio, Texas, United States, 78229
- Research Site
-
San Antonio, Texas, United States, 78215
- Research Site
-
San Antonio, Texas, United States, 78205
- Research Site
-
Tyler, Texas, United States, 75701
- Research Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22033
- Research Site
-
Mechanicsville, Virginia, United States, 23116
- Research Site
-
Norfolk, Virginia, United States, 23502
- Research Site
-
-
West Virginia
-
Bluefield, West Virginia, United States, 24701
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
- Subject is 18 years of age or older.
- Subject must be receiving hemodialysis 3 times weekly for at least 3 months
- Subject agrees to not participate in another study of an investigational agent during the study.
- Other Inclusion Criteria may apply
Exclusion Criteria:
- Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.
- Other investigational procedures while participating in this study are excluded.
- Anticipated or scheduled parathyroidectomy during the study period.
- Subject has received a parathyroidectomy within 3 months prior to dosing.
- Anticipated or scheduled kidney transplant during the study period.
- Subject has known sensitivity to any of the products or components to be administered during dosing.
- Subject has participated in a prior clinical trial of AMG 416 (also referred to as KAI-4169).
- Subject has received cinacalcet within the 4 weeks prior to screening labs (treatment with cinacalcet is prohibited during the study).
- Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
- Other Exclusion Criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Etelcalcetide
Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
|
Administered intravenously three times per week.
The starting dose was 5 mg.
The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week.
The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Other Names:
|
Placebo Comparator: Placebo
Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
|
Administered intravenously (IV) three times per week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase
Time Frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).
|
Participants who did not have any scheduled assessments during the EAP were considered non-responders.
|
Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Mean Predialysis Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase
Time Frame: Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
Participants who had no scheduled assessments during the EAP were considered non-responders.
|
Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
Percent Change From Baseline in Predialysis PTH During the Efficacy Assessment Phase
Time Frame: Baseline and the Efficacy Assessment Phase (Week 20 to Week 27)
|
Baseline and the Efficacy Assessment Phase (Week 20 to Week 27)
|
|
Percent Change From Baseline in Predialysis Corrected Calcium During the Efficacy Assessment Phase
Time Frame: Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
|
Percent Change From Baseline in Predialysis Corrected Calcium Phosphorus Product During the Efficacy Assessment Phase
Time Frame: Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
|
Percent Change From Baseline in Predialysis Phosphorus During the Efficacy Assessment Phase
Time Frame: Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
Baseline and the efficacy assessment phase (Week 20 to Week 27)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.
- Kroenke MA, Weeraratne DK, Deng H, Sloey B, Subramanian R, Wu B, Serenko M, Hock MB. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments. J Immunol Methods. 2017 Jun;445:37-44. doi: 10.1016/j.jim.2017.03.005. Epub 2017 Mar 6.
- Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2.
- Stollenwerk B, Iannazzo S, Cooper K, Belozeroff V. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. J Med Econ. 2017 Oct;20(10):1110-1115. doi: 10.1080/13696998.2017.1360309. Epub 2017 Aug 14.
- Chen P, Narayanan A, Wu B, Gisleskog PO, Gibbs JP, Chow AT, Melhem M. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Clin Pharmacokinet. 2018 Jan;57(1):71-85. doi: 10.1007/s40262-017-0550-4.
- Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One. 2019 Mar 15;14(3):e0213774. doi: 10.1371/journal.pone.0213774. eCollection 2019.
- Cunningham J, Block GA, Chertow GM, Cooper K, Evenepoel P, Iles J, Sun Y, Urena-Torres P, Bushinsky DA. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019 Apr 16;4(7):987-994. doi: 10.1016/j.ekir.2019.04.010. eCollection 2019 Jul.
- Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM, Sun Y, Tomlin H, Vervloet M, Oberbauer R. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin Kidney J. 2019 Apr 26;13(1):75-84. doi: 10.1093/ckj/sfz034. eCollection 2020 Feb.
- Hain D, Tomlin H, Gibson C. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective. Nephrol Nurs J. 2019 May-Jun;46(3):315-290.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 12, 2013
Primary Completion (Actual)
May 22, 2014
Study Completion (Actual)
June 12, 2014
Study Registration Dates
First Submitted
February 5, 2013
First Submitted That Met QC Criteria
February 6, 2013
First Posted (Estimate)
February 7, 2013
Study Record Updates
Last Update Posted (Actual)
August 26, 2019
Last Update Submitted That Met QC Criteria
August 9, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20120229
- KAI-4169-006 (Other Identifier: KAI Pharmaceuticals, Inc (wholly owned subsidiary of Amgen Inc.))
- 2012-002805-23 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperparathyroidism, Secondary
-
The Second Hospital of Nanjing Medical UniversityRecruitingSecondary Hyperparathyroidism;ParathyroidectomyChina
-
Phramongkutklao College of Medicine and HospitalCompletedAlfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
-
Min-Sheng General HospitalTaipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaboratorsCompletedHyperparathyroidism; Secondary, RenalTaiwan
-
Chang Gung Memorial HospitalCompletedSecondary Hyperparathyroidism Due to Renal CausesTaiwan
-
Fundación SenefroAbbVie; Effice Servicios Para la Investigacion S.L.CompletedSecondary Hyperparathyroidism Due to Renal CausesSpain
-
Shanghai Zhongshan HospitalUnknownHyperparathyroidism; Secondary, Renal
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Active, not recruiting
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Deltanoid PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States
Clinical Trials on Etelcalcetide
-
Thomas Nickolas, MD MSCompletedVascular Calcification | Chronic Kidney Disease Mineral and Bone Disorder | Hyperparathyroidism; Secondary, Renal | Renal OsteodystrophyUnited States
-
Prim. Priv. Doz. Dr. Daniel CejkaAmgenCompleted
-
AmgenCompletedChronic Kidney Disease, Secondary HyperparathyroidismBelgium, United States, Germany, Poland, United Kingdom, Lithuania
-
AmgenRecruitingChronic Kidney Disease | Secondary HyperparathyroidismKorea, Republic of, United States, Turkey, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Ukraine
-
AmgenCompletedHyperparathyroidism, SecondaryUnited States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Australia, Austria, Israel, Czechia, Hungary, Netherlands, Poland, France, Russian Federation, Sweden
-
KAI PharmaceuticalsNucleus Network LtdCompletedHyperparathyroidism, SecondaryAustralia
-
AmgenCompletedSecondary HyperparathyroidismChina
-
KAI PharmaceuticalsCompletedHyperparathyroidism, SecondaryUnited States, Australia
-
AmgenCompletedSecondary Hyperparathyroidism in Patients With ESRD on HemodialysisUnited States
-
KAI PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States